Take a look at some of Wednesday's midday movers:
Regeneron moved higher after biotechnology company and Sanofi announced promising Phase 3 trials for their injectable cholesterol drug, Alirocumab. When used by itself, it cut levels of bad LDL cholesterol almost in half.
Abbott Labs gained after the pharmaceutical company reported better-than-expected quarterly earnings, helped by cost cutting and lower taxes. Revenue rose 2 percent to $5.37 billion, a bit less than what the Street was expecting
Sprint climbed after Macquarie upgraded the stock to "outperform" from "neutral" on valuation. The company is also a favorite of hedge fund billionaire Leon Cooperman.